Treatment options for visceral leishmaniasis

References

• Desjeux P. Leishmaniasis. Public health aspects and control. Clin. Dermatol.14, 417–423 (1996).
   PubMed Web of Science ®Google Scholar
• Murray HW. Kala-azar – progress against a neglected disease. N. Engl. J. Med.347, 1792–1794 (2002).
   Google Scholar
• Herwaldt BL. Leishmaniasis. Lancet354, 1109–1199 (1999).
   Google Scholar
• Desjeux P. The increase in risk factors for Leishmania world wide. Trans. R. Soc. Trop. Med. Hyg.95, 239–143 (2001).
   PubMed Web of Science ®Google Scholar
• WHO. The world health report 2004. WHO, Geneva, Switzerland (2004).
   Google Scholar
• Desjeux P. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis.27, 305–318 (2004).
   PubMed Web of Science ®Google Scholar
• WHO. The world health report 2001. WHO, Geneva, Switzerland (2001).
   Google Scholar
• WHO. The world health report 2003. WHO, Geneva, Switzerland (2003).
   Google Scholar
• Ashford RW, Thomson MC. Visceral leishmaniasis in Sudan. A delayed development disaster? Ann. Trop. Med. Parasitol.85(5), 571–572 (1991).
   PubMed Web of Science ®Google Scholar
• Marlet MV, Sang DK, Ritmeijer K, Muga RO, Onsongo J, Davidson RN. Emergence or re-emergence of visceral leishmaniasis in areas of Somalia, north-eastern Kenya, and south-eastern Ethiopia in 2000–01. Trans. R. Soc. Trop. Med. Hyg.97(5), 515–518 (2003).
   PubMed Web of Science ®Google Scholar
• Sundar S, Rai M. The treatment of visceral leishmaniasis. Expert Opin. Pharmacother.6(16), 2821–2829 (2005).
   PubMed Web of Science ®Google Scholar
• Ritmeijer K, Davidson RN. Médecins Sans Frontières interventions against kala-azar in the Sudan, 1989–2003. Royal Society of Tropical Medicine and Hygiene Joint Meeting with Médecins Sans Frontières at Manson House, London, 20 March 2003. Field research in humanitarian medical programmes. Trans. R. Soc. Trop. Med. Hyg.97, 609–613 (2003).
   PubMed Web of Science ®Google Scholar
• Badaró R, Jones T, Carvalho E et al. New perspectives on a subclinical form of visceral leishmaniasis. J. Infect. Dis.154, 1003–1011 (1986).
   PubMed Web of Science ®Google Scholar
• Gama ME, Costa JM, Gomes CM, Corbett CE. Subclinical form of the American visceral leishmaniasis. Mem. Inst. Oswaldo Cruz99(8), 889–893 (2004).
   PubMed Web of Science ®Google Scholar
• Zijlstra EE, El-Hassan AM. Leishmaniasis in Sudan. Visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg.95, S27–S58 (2001).
   PubMed Web of Science ®Google Scholar
• Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann. Trop. Med. Parasitol.97, S3–S15 (2003).
   PubMed Web of Science ®Google Scholar
• Seaman J, Mercer AJ, Sondorp E, Herwaldt BL. Epidemic visceral leishmaniasis in Southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann. Intern. Med.124(7), 664–672 (1996).
   PubMed Web of Science ®Google Scholar
• Seaman J, Mercer AJ, Sondorp E. The epidemic of visceral leishmaniasis in Western Upper Nile, Southern Sudan: course and impact from 1984 to 1994. Int. J. Epidemiol.24(4), 862–871 (1996).
   Google Scholar
• Kumar R, Kumar P, Chowdhary RK et al. Kala-azar epidemic in Varanasi district, India. Bull. World Health Organ.77(5), 371–374 (1999).
   PubMed Web of Science ®Google Scholar
• Murray H. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert Rev. Anti Infect. Ther.2(2), 279–292 (2004).
   PubMedGoogle Scholar
• Sundar S, Murray H. Availability of miltefosine for the treatment of kala-azar in India. Bull. World Health Organ.83(5), 394–395 (2005).
   PubMed Web of Science ®Google Scholar
• Bern C, Chowdhury R. The epidemiology of visceral leishmaniasis in Bangladesh and prospects for improved control. IJMR (2006) (In press).
   Google Scholar
• Directorate General for Health Services 2005. National Kala Azar Surveillance Data, Dhaka, Bangladesh: government of Bangladesh (2005).
   Google Scholar
• Ahluwalia IB, Bern C, Costa C et al. Leishmaniasis: consequences of a neglected disease in a community. Am. J. Trop. Hyg.69(99), 624–628 (2003).
   PubMed Web of Science ®Google Scholar
• Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans. R. Soc. Trop. Med. Hyg.95, 1–5 (2001).
   PubMed Web of Science ®Google Scholar
• Davidson RN. AIDS and leishmaniasis. Genitourin. Med.73, 237–239 (1997).
   PubMedGoogle Scholar
• Bogdan C, Rollinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. Int. J. Parasitol.28, 121–134 (1998).
   PubMed Web of Science ®Google Scholar
• Faraut-Gambarelli F, Piarroux R, Deniau M et al. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob. Agents Chemother.41, 827–830 (1997).
   PubMed Web of Science ®Google Scholar
• Villanueva JL, Alarcon A, Bernabeu-Wittel M et al. Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy. Eur. J. Clin. Microbiol. Infect. Dis.19, 798–801 (2000).
   PubMed Web of Science ®Google Scholar
• Berenguer J, Cosin J, Miralles P, Lopez JC, Padilla B. Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS14, 2946–2948 (2000).
   PubMed Web of Science ®Google Scholar
• Desjeux P. Urbanization: an increasing risk factor for leishmaniasis. Wkly Epidemiol. Rec.77, 44 (2002).
   Google Scholar
• Lopez-Velez R, Casado JL, Pintado V. Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART). Clin. Microbiol. Infect.7, 394–395 (2001).
   PubMed Web of Science ®Google Scholar
• Lyons L, Veeken H, Long J. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop. Med. Int. Health8(8), 733–739 (2003).
   PubMed Web of Science ®Google Scholar
• Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect. Dis.3, 87–98 (2003).
   PubMed Web of Science ®Google Scholar
• Thakur CP, Narain S, Kumar N, Hassan SM, Jha DK, Kumar A. Amphotericin B is superior to sodium stibogluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Ann. Trop. Med. Parasitol.92, 611–616 (1997).
   Google Scholar
• Thakur CP, Kumar K. Efficacy of prolonged therapy with stibogluconate in post kala azar dermal leishmaniasis. Ind. J. Med. Res.91, 144–148 (1990).
   PubMed Web of Science ®Google Scholar
• Addy M, Nandy A. Ten years of kala-azar in west Bengal, Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull. World Health Organ.70, 341–346 (1992).
   PubMed Web of Science ®Google Scholar
• Goodwin LG. Pentostam (sodium stibogluconate); a 50-year personal reminiscence. Trans. R. Soc. Trop. Med. Hyg.89, 339–341 (1995).
   PubMed Web of Science ®Google Scholar
• Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health6, 849–854 (2001).
   PubMed Web of Science ®Google Scholar
• Rijal S, Chappuis F, Singh R et al. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans. R. Soc. Trop. Med. Hyg.97, 350–354 (2003).
   PubMed Web of Science ®Google Scholar
• Gradoni L, Gramiccia M, Scalone A. Visceral leishmaniasis treatment, Italy. Emerg. Infect. Dis.9, 1617–1620 (2003).
   PubMed Web of Science ®Google Scholar
• Berman JD, Lee LS. Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages. J. Parasitol.70(2), 220–225 (1984).
   PubMed Web of Science ®Google Scholar
• Sundar S, Sinha PR, Agrawal NK et al. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high osmolarity lot of sodium antimony gluconate. Am. J. Trop. Med. Hyg.59, 139–143 (1998).
   PubMed Web of Science ®Google Scholar
• Deps PD, Viana MC, Falqueto A, Dietze R. Comparative study between sodium stibogluconate BP88 (Shandong Xinhua – China) and meglumine antimoniate (Rhodia – Brazil) on the treatment of cutaneous leishmaniasis, in the endemic area Corte de Pedra, Bahia, Brazil. Rev. Soc. Bras. Med. Trop.33, 535–543 (2000).
   PubMedGoogle Scholar
• Rijal S, Chappuis F, Singh R, Boelaert M, Loutan L, Koirala S. Sodium stibogluconate cardiotoxicity and safety of generics. Trans. R. Soc. Trop. Med. Hyg.97(5), 597–598 (2003).
   PubMed Web of Science ®Google Scholar
• Moore E, O’Flaherty D, Heuvelmans H et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull. World Health Organ.79(5), 388–393 (2001).
   PubMed Web of Science ®Google Scholar
• Veeken H, Ritmeijer K, Seaman J, Davidson RN. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop. Med. Int. Health5, 312–317 (2000).
   PubMed Web of Science ®Google Scholar
• Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am. J. Trop. Med. Hyg.46(3), 296–306 (1992).
   PubMed Web of Science ®Google Scholar
• MSF Holland Northern Bangladesh assessment 17–27 October 2005 (internal report). (2005).
   Google Scholar
• Sundar S, More DK, Singh MK et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis.31, 1104–1106 (2000).
   PubMed Web of Science ®Google Scholar
• Collin S, Davidson R, Ritmeijer K et al. Conflict and kala-azar: determination of adverse outcomes of kala azar among patients in Southern Sudan. Clin. Infect. Dis.38, 612–619 (2004).
   PubMed Web of Science ®Google Scholar
• Kanyok TP, Reddy MV, Chinnaswamy J, Danziger LH, Gangadharam PR. In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains. Antimicrob. Agents Chemother.38(2), 170–173 (1994).
   PubMed Web of Science ®Google Scholar
• Kellina OI. Test-trials of the chemotherapeutic monomycin activity in experimental cutaneous leishmaniasis in albino mice (Russian; English abstract). Med. Parazitol. (Mosk.)32, 572 (1963).
   PubMedGoogle Scholar
• Neal RA. The effect of antibiotics of the neomycin group on experimental cutaneous leishmaniasis. Ann. Trop. Med. Parasitol.62, 54–62 (1968).
   PubMed Web of Science ®Google Scholar
• El-On J, Jacobs GP, Witztum E, Greenblatt CL. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrob. Agents Chemother.26, 745–751 (1984).
   PubMed Web of Science ®Google Scholar
• Teklemariam S, Hiwot AG, Frommel D, Miko TL, Ganlov G, Bryceson A. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans. R. Soc. Trop. Med. Hyg.88(3), 334–339 (1994).
   PubMed Web of Science ®Google Scholar
• Neal RA, Allen S, McCoy N, Olliaro P, Croft SL. The sensitivity of Leishmania species to aminosidine. J. Antimicrob. Chemother.35, 577–584 (1995).
   PubMed Web of Science ®Google Scholar
• Maarouf M, Lawrence F, Croft SL, Robert-Gero M. Ribosomes of Leishmania are a target for the aminoglycosides. Parasitol. Res.81, 421–425 (1995).
   PubMed Web of Science ®Google Scholar
• Callahan HL, Portal AC, Devereaux R, Grogl M. An axenic amastigote system for drug screening. Antimicrob. Agents Chemother.41, 818–822 (1997).
   PubMed Web of Science ®Google Scholar
• Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans. R. Soc. Trop. Med. Hyg.84(2), 221–225 (1990).
   PubMed Web of Science ®Google Scholar
• Thakur CP, Kanyok TP, Pandey AK et al. A prospective randomized, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone. Trans. R. Soc. Trop. Med. Hyg.94(4), 429–431(2000).
   PubMed Web of Science ®Google Scholar
• Thakur CP, Olliaro P, Gothoskar S et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin) – antimonial combinations, a pilot study in Bihar, India. Trans. R. Soc. Trop. Med. Hyg.86(6), 615–616 (1992).
   PubMed Web of Science ®Google Scholar
• Thakur CP, Bhowmick S, Dolfi L, Olliaro P. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomised dose-finding clinical trial. Trans. R. Soc. Trop. Med. Hyg.89(2), 219–223 (1995).
   PubMed Web of Science ®Google Scholar
• Seaman J, Pryce D, Sondorp HE, Moody A, Bryceson AD, Davidson RN. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J. Infect. Dis.168(3), 715–720 (1993).
   PubMed Web of Science ®Google Scholar
• Paromomycin/SSG Evaluation South Sudan-statistical analysis. Koert Ritmeijer, MSF Holland.
   Google Scholar
• Sinha PK, Bhattacharya SK, Thakur CP, Jha TK, Sundar S. Paromomycin as a new cure for visceral leishmaniasis in pediatric patients: preliminary analysis of a Phase III randomized controlled clinical trial. Presented at the 3rd International Congress on Leishmaniasis. Palermo, Sicily, Italy, April 10–15 (2005).
   Google Scholar
• Jha TK, Sundar S, Bhattacharya SK, Sinha PK, Thakur CP. Paromomcyin as a new cure for visceral leishmaniasis: preliminary results of a Phase III randomized controlled trial of efficacy and safety. Presented at the 3rd International Congress on Leishmaniasis. Palermo, Sicily, Italy, April 10–15 (2005).
   Google Scholar
• Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SI, Desjeux P. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet2, 34–41 (2002).
   Google Scholar
• Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop. Med. Int. Health6, 928–934 (2001).
   PubMed Web of Science ®Google Scholar
• Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr. Opin. Infect. Dis.15, 593–598 (2002).
   PubMed Web of Science ®Google Scholar
• Sundar S, Rai M. Treatment of visceral leishmaniasis. Expert Opin. Pharmacother.6, 2821–2829 (2005).
   PubMed Web of Science ®Google Scholar
• Davidson RN, di Martino L, Gradoni L et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin. Infect. Dis.22, 938–943 (1996).
   PubMed Web of Science ®Google Scholar
• Berman JD, Badaro R, Thakur CP et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. World Health Organ.76, 25–32 (1998).
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am. J. Trop. Med. Hyg.66, 143–146 (2002).
   PubMed Web of Science ®Google Scholar
• Mueller M, Ritmeijer K, Balasegaram M, Koummuki M, Santana MR, Davidson R. Unresponsiveness to AmBisome in some Sudanese patients with kala azar. Trans. R. Soc. Trop. Med. Hyg. (2006) (In press).
   PubMedGoogle Scholar
• Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin. Infect. Dis.38, 377–383 (2004).
   PubMed Web of Science ®Google Scholar
• Thakur CP, Jha TK. Efficacy and safety of three different regimens of intravenous amphotericin B emulsion for treatment naïve and treatment resistant cases of kala azar. Clinical study report. (2003).
   Google Scholar
• Seaman J, Boer C, Wilkinson R, de Jong J, de Wilde E, Sondorp E. Liposomal amphotericin B (AmBisome) in the treatment of complicated kalaazar under field conditions. Clin. Infect. Dis.21, 188–193 (1995).
   PubMed Web of Science ®Google Scholar
• Liposomal amphotericin B in visceral leishmaniasis treatment. Proceedings of a WHO/TDR consultation, April 2005. Clin. Infect. Dis. (2006) (In press).
   Google Scholar
• Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ323, 419–422 (2001).
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin. Infect. Dis.37, 800–804 (2003).
   PubMed Web of Science ®Google Scholar
• Gangneux JP, Sulahian A, Garin YJ, Farinotti R, Derouin F. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Antimicrob. Agents Chemother.40, 1214–1218 (1996).
   PubMed Web of Science ®Google Scholar
• Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother.38, 1041–1047 (1996).
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP et al. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med.347(22), 1739–1746 (2002).
   PubMed Web of Science ®Google Scholar
• Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A. Trial of oral miltefosine for visceral leishmaniasis. Lancet352(9143), 1821–1823 (1998).
   PubMed Web of Science ®Google Scholar
• Bhattacharya SK, Jha TK, Sundar S et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin. Infect. Dis.38, 217–221 (2004).
   PubMed Web of Science ®Google Scholar
• Perez-Victoria FJ, Sanchez-Canete M, Castanys S, Gamarro F. Experimental miltefosine resistance: Leishmania sensitivity to miltefosine depends on drug uptake mechanism. Presented at the 3rd International Congress on Leishmaniasis. Palermo, Sicily, Italy, April 10–15 (2005).
   Google Scholar
• Olliari P, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen J, Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004. Lancet5, 763–774 (2005).
   Web of Science ®Google Scholar
• Sindermann H, Engel KR, Fischer C, Bommer W. Oral miltefosine for leishmaniasis in immunocompromosed patients: compassionate use in 39 patients with HIV infection. Clin. Infect. Dis.39, 1520–1523 (2004).
   PubMed Web of Science ®Google Scholar
• Neal RA, Croft SL, Nelson DJ. Anti-leishmanial effect of allopurinol ribonucleoside and the related compounds, allopurinol, thiopurinol, thiopurinol ribonucleoside, and of formycin B, sinefungin and the lepidine WR6026. Trans. R. Soc. Trop. Med. Hyg.79, 122–128 (1985).
   PubMed Web of Science ®Google Scholar
• Jha TK, Sundar S, Thakur CP, Felton JM, Sabin AJ, Horton J. A Phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am. J. Trop. Med. Hyg.73, 1005–1011 (2005).
   PubMed Web of Science ®Google Scholar
• Wasunna MK, Rashid JR, Mbui J et al. A Phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am. J. Trop. Med. Hyg.73, 871–876 (2005).
   PubMed Web of Science ®Google Scholar
• Berman J. Clinical status of agents being developed for leishmaniasis. Expert Opin. Investig. Drugs14, 337–346 (2005).
   Google Scholar
• Collin SM, Coleman PG, Ritmeijer K, Davidson RN. Unseen kala-azar deaths in south Sudan (1999–2002). Trop. Med. Intl Health11, 509–512 (2006).
   PubMed Web of Science ®Google Scholar
• Goswami RP, Bairagi B, Kundu PK. K39 strip test-easy, reliable and cost-effective field diagnosis for visceral leishmaniasis in India. J. Assoc. Physicians India51, 759–761 (2003).
   PubMedGoogle Scholar
• Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet366, 1561–1577 (2005).
   PubMed Web of Science ®Google Scholar
• Molina R, Gradoni L, Alvar J. HIV and the transmission of Leishmania. Ann. Trop. Med. Parasitol.97, S29–S45 (2003).
   PubMed Web of Science ®Google Scholar
• Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob. Agents Chemother.50, 73–79 (2006).
   PubMed Web of Science ®Google Scholar